To compare the effects of warfarin, low-dose aspirin, or placebo on the incidence of thromboembolic complications in patients with chronic non-rheumatic atrial fibrillation.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Warfarin (Coumadin®)Drug
Intervention Desc: Anticoagulant (Vitamin K antagonist)
Placebo-controlled, randomized trial.
Eligible patients were randomized to receive warfarin (openly), or to blindly receive either aspirin (75 mg once daily) or placebo. Follow up exams were performed at three months and six months, then every six months for two years.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Stroke, TIA, or embolic complications at two years.|